



HEALTH ALERT NETWORK BROADCAST
MESSAGE ID: 09012020 10:00
FROM: CO-CDPHE
SUBJECT: HAN Advisory - Sanofi-Aventis to Discontinue Three Rifampin Products
RECIPIENTS: Local public health agencies / IPs / ID Physicians
RECIPIENT INSTRUCTIONS: Local Public Health Agencies -For your information

HEALTH ADVISORY | Sanofi-Aventis to Discontinue Three Rifampin Products | Sep. 1, 2020

Health care providers: Please distribute widely in your office

Key points

- Sanofi-Aventis is permanently discontinuing Rifadin, Rifamate, and Rifater.
- Rifamate and Rifater are primarily used to treat tuberculosis, but Rifadin (rifampin capsules) may be used to treat other infections.
- If your facility prescribes any of these three drugs, it is recommended that you assess availability with your pharmacy.

Background information

Rifampin is a core drug in many tuberculosis treatment regimens and also used in the treatment of other bacterial diseases. Sanofi-Aventis produces three rifampin-containing drugs: Rifadin, Rifamate, and Rifater. All three will be permanently discontinued at some point in the future. Rifamate (a combination of isoniazid and rifampin) and Rifater (a combination of isoniazid, rifampin, and pyrazinamide) are used primarily for tuberculosis treatment. Rifadin (rifampin 150mg and 300mg capsules) may be used to treat other conditions as well.

The timeline for the discontinuation of these drugs is not currently known. The FDA is currently investigating the status of rifampin produced by other manufacturers.

Recommendations / guidance

Providers who routinely prescribe rifampin are advised to assess rifampin availability with your pharmacy.

For more information regarding drug shortages and discontinuations

<https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.

CDPHE Disease Reporting Line: 303-692-2700 or 303-370-9395 (after hours)